Covaxin, Bharat Biotech’s COVID-19 vaccine candidate, has been developed in collaboration with the ICMR and NIV
The AIIMS Ethics Committee on Saturday gave …
Covaxin, Bharat Biotech’s COVID-19 vaccine candidate, has been developed in collaboration with the ICMR and NIV
The AIIMS Ethics Committee on Saturday gave its nod for a human clinical trial of the indigenously developed COVID-19 vaccine candidate Covaxin following which the premier hospital is likely to begin the exercise by enrolling healthy volunteers from Monday.
AIIMS-Delhi is among the 12 sites selected by the Indian Council for Medical Research (ICMR) for conducting phase I and II human trials of Covaxin. In phase I, the vaccine would be tested on 375 volunteers and a maximum of 100 of them would be from AIIMS.
« The AIIMS Ethics Committee gave its approval for starting the human clinical trial of the indigenously developed Covaxin today. Healthy volunteers having no comorbid conditions and without a history of COVID-19, aged more than 18 years and less than 55 years, would be eligible to participate in the randomised, double-blind, placebo-controlled clinical trial, » Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS said.
